Current and emerging pharmacotherapies for primary CNS lymphoma

Prathima Prodduturi, Philip Jay Bierman

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Primary central nervous system lymphoma (PCNSL) constitutes a rare group of extranodal non-Hodgkin's lymphoma (NHL) primarily of B cell origin. It occurs in both immuno-competent and immune-compromised patients. High dose methotrexate (HD-MTX) based chemotherapy is the standard therapy. Chemotherapy with whole brain radiation therapy (WBRT) improves response rates and survival compared with WBRT alone. However, due to the increased risk for neurotoxicity with WBRT, recent studies have focused on using chemotherapy alone. Methotrexate based multi-agent chemotherapy without WBRT is associated with similar treatment rates and survival compared with regimens that include WBRT although controlled trials have not been performed. Because of the low incidence of this disease, it is difficult to conduct randomized controlled trials. In this article we have discussed about the past, present and emerging treatment options in patients with PCNSL.

Original languageEnglish (US)
Pages (from-to)219-231
Number of pages13
JournalClinical Medicine Insights: Oncology
Volume6
DOIs
StatePublished - Jan 1 2012

Fingerprint

Lymphoma
Radiotherapy
Drug Therapy
Brain
Methotrexate
Survival Rate
Central Nervous System
Non-Hodgkin's Lymphoma
B-Lymphocytes
Therapeutics
Randomized Controlled Trials
Incidence

Keywords

  • Chemotherapy
  • Hematopoietic stem cell transplantation
  • Methotrexate
  • Primary CNS lymphoma
  • Whole brain radiation therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Current and emerging pharmacotherapies for primary CNS lymphoma. / Prodduturi, Prathima; Bierman, Philip Jay.

In: Clinical Medicine Insights: Oncology, Vol. 6, 01.01.2012, p. 219-231.

Research output: Contribution to journalReview article

@article{8e5b9e7dee4e4e59ae93b18a72a10c54,
title = "Current and emerging pharmacotherapies for primary CNS lymphoma",
abstract = "Primary central nervous system lymphoma (PCNSL) constitutes a rare group of extranodal non-Hodgkin's lymphoma (NHL) primarily of B cell origin. It occurs in both immuno-competent and immune-compromised patients. High dose methotrexate (HD-MTX) based chemotherapy is the standard therapy. Chemotherapy with whole brain radiation therapy (WBRT) improves response rates and survival compared with WBRT alone. However, due to the increased risk for neurotoxicity with WBRT, recent studies have focused on using chemotherapy alone. Methotrexate based multi-agent chemotherapy without WBRT is associated with similar treatment rates and survival compared with regimens that include WBRT although controlled trials have not been performed. Because of the low incidence of this disease, it is difficult to conduct randomized controlled trials. In this article we have discussed about the past, present and emerging treatment options in patients with PCNSL.",
keywords = "Chemotherapy, Hematopoietic stem cell transplantation, Methotrexate, Primary CNS lymphoma, Whole brain radiation therapy",
author = "Prathima Prodduturi and Bierman, {Philip Jay}",
year = "2012",
month = "1",
day = "1",
doi = "10.4137/CMO.S7752",
language = "English (US)",
volume = "6",
pages = "219--231",
journal = "Clinical Medicine Insights: Oncology",
issn = "1179-5549",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Current and emerging pharmacotherapies for primary CNS lymphoma

AU - Prodduturi, Prathima

AU - Bierman, Philip Jay

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Primary central nervous system lymphoma (PCNSL) constitutes a rare group of extranodal non-Hodgkin's lymphoma (NHL) primarily of B cell origin. It occurs in both immuno-competent and immune-compromised patients. High dose methotrexate (HD-MTX) based chemotherapy is the standard therapy. Chemotherapy with whole brain radiation therapy (WBRT) improves response rates and survival compared with WBRT alone. However, due to the increased risk for neurotoxicity with WBRT, recent studies have focused on using chemotherapy alone. Methotrexate based multi-agent chemotherapy without WBRT is associated with similar treatment rates and survival compared with regimens that include WBRT although controlled trials have not been performed. Because of the low incidence of this disease, it is difficult to conduct randomized controlled trials. In this article we have discussed about the past, present and emerging treatment options in patients with PCNSL.

AB - Primary central nervous system lymphoma (PCNSL) constitutes a rare group of extranodal non-Hodgkin's lymphoma (NHL) primarily of B cell origin. It occurs in both immuno-competent and immune-compromised patients. High dose methotrexate (HD-MTX) based chemotherapy is the standard therapy. Chemotherapy with whole brain radiation therapy (WBRT) improves response rates and survival compared with WBRT alone. However, due to the increased risk for neurotoxicity with WBRT, recent studies have focused on using chemotherapy alone. Methotrexate based multi-agent chemotherapy without WBRT is associated with similar treatment rates and survival compared with regimens that include WBRT although controlled trials have not been performed. Because of the low incidence of this disease, it is difficult to conduct randomized controlled trials. In this article we have discussed about the past, present and emerging treatment options in patients with PCNSL.

KW - Chemotherapy

KW - Hematopoietic stem cell transplantation

KW - Methotrexate

KW - Primary CNS lymphoma

KW - Whole brain radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=84863967360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863967360&partnerID=8YFLogxK

U2 - 10.4137/CMO.S7752

DO - 10.4137/CMO.S7752

M3 - Review article

VL - 6

SP - 219

EP - 231

JO - Clinical Medicine Insights: Oncology

JF - Clinical Medicine Insights: Oncology

SN - 1179-5549

ER -